Cantargia AB has completed a GLP toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN-10, showing that CAN-10 was well tolerated when administered over 6 weeks.
Ono Pharmaceutical Co. Ltd. has entered an option and research collaboration agreement with Monash University to discover and develop antibodies targeting G protein-coupled receptors (GPCRs) with the aim of creating novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a novel oncolytic virus (OV) for intravenous administration in patients with advanced non-small-cell lung cancer (NSCLC). Enrollment is expected to open in the first half of this year.
Abbvie Inc. and Immunome Inc. have announced a worldwide collaboration and option agreement for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's discovery engine.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Hansoh Pharmaceutical Group Company Ltd. have established an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for its selected fully human antibody molecules against a designated target for development, manufacturing and commercialization globally.
Triple-negative breast cancer (TNBC) has a diverse etiology, with high unmet clinical needs. Researchers from Tavotek Biotherapeutics (Hong Kong) Ltd. presented data on TAVO-412, a trispecific EGFR/cMET/VEGF (2:1:1 binding arm ratio) antibody for the potential treatment of TNBC.
Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like trispecific antibody PIT-565, which engages CD19+ on tumor cells, and CD3 (TCR signaling component) and CD2 (a costimulatory receptor) on T cells simultaneously to redirect T-cell cytotoxicity toward CD19-positive malignant B cells, has been designed to avoid T-cell exhaustion.
Killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3) is a member of the killer cell Ig-like (KIR) receptor family. When KIR3DL3 is expressed on T and natural killer (NK) cells in the tumor microenvironment, it suppresses immune responses following engagement with HHLA2, suggesting that the KIR3DL3-HHLA2 axis potentially represents a novel immune checkpoint pathway and that blockade of KIR3DL3 signaling could promote antitumor immunity.
Sensei Biotherapeutics Inc. has entered into a sponsored research agreement with Washington University in St. Louis to support development of SNS-101, a conditionally active V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA)-blocking antibody.
Regeneron Pharmaceuticals Inc. has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with Abcellera Biologics Inc. as part of a multitarget collaboration between the companies, into further preclinical development.
RSS
